Peter Y K Van den Bergh1, Françoise Piéret2, John L Woodard3, Shahram Attarian4, Aude-Marie Grapperon4, Guillaume Nicolas5, Marion Brisset5, Julien Cassereau6, Yusuf A Rajabally7, Vinciane Van Parijs1, Donatienne Verougstraete8, Philippe Jacquerye9, Jean-Marc Raymackers9, Céline Redant10, Claure Michel11, Emilien Delmont12. 1. Neuromuscular Reference Centre, University Hospital St-Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium. 2. St Elisabeth Hospital, Brussels, Belgium. 3. Department of Psychology, Wayne State University, Detroit, Michigan, USA. 4. Centre de référence des maladies Neuromusculaires et la SLA, Hôpital de la Timone, Marseille, France. 5. Service de neurologie, Hôpital Raymond Poincaré, Garches, France. 6. Centre de Référence Maladies Neuromusculaires de l'Enfant et de l'Adulte Nantes-Angers, Centre Hospitalier Universitaire d'Angers, Angers, France. 7. Regional Neuromuscular Service, Neurology, University Hospitals Birmingham, Birmingham, UK. 8. Parc Leopold Hospital, Brussels, Belgium. 9. St-Pierre Hospital, Ottignies, Belgium. 10. St-Luc Hospital, Bouge, Belgium. 11. Jolimont Hospital, Mons, Belgium. 12. Centre de référence des maladies Neuromusculaires et la SLA. Hôpital de la Timone, Marseille, France.
Abstract
INTRODUCTION: There is uncertainty as to whether the Guillain-Barré syndrome (GBS) subtypes, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), can be diagnosed electrophysiologically. METHODS: We prospectively included 58 GBS patients. Electrodiagnostic testing (EDX) was performed at means of 5 and 33 days after disease onset. Two traditional and one recent criteria sets were used to classify studies as demyelinating or axonal. Results were correlated with anti-ganglioside antibodies and reversible conduction failure (RCF). RESULTS: No classification shifts were observed, but more patients were classified as axonal with recent criteria. RCF and anti-ganglioside antibodies were present in both subtypes, more frequently in the axonal subtype. DISCUSSION: Serial EDX has no effect on GBS subtype proportions. The absence of exclusive correlation with RCF and anti-ganglioside antibodies may challenge the concept of demyelinating and axonal GBS subtypes based upon electrophysiological criteria. Frequent RCF indicates that nodal/paranodal alterations may represent the main pathophysiology. Muscle Nerve, 2018.
INTRODUCTION: There is uncertainty as to whether the Guillain-Barré syndrome (GBS) subtypes, acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and acute motor axonal neuropathy (AMAN), can be diagnosed electrophysiologically. METHODS: We prospectively included 58 GBSpatients. Electrodiagnostic testing (EDX) was performed at means of 5 and 33 days after disease onset. Two traditional and one recent criteria sets were used to classify studies as demyelinating or axonal. Results were correlated with anti-ganglioside antibodies and reversible conduction failure (RCF). RESULTS: No classification shifts were observed, but more patients were classified as axonal with recent criteria. RCF and anti-ganglioside antibodies were present in both subtypes, more frequently in the axonal subtype. DISCUSSION: Serial EDX has no effect on GBS subtype proportions. The absence of exclusive correlation with RCF and anti-ganglioside antibodies may challenge the concept of demyelinating and axonal GBS subtypes based upon electrophysiological criteria. Frequent RCF indicates that nodal/paranodal alterations may represent the main pathophysiology. Muscle Nerve, 2018.
Authors: Judith Drenthen; Badrul Islam; Zhahirul Islam; Quazi D Mohammad; Ellen M Maathuis; Gerhard H Visser; Pieter A van Doorn; Joleen H Blok; Hubert P Endtz; Bart C Jacobs Journal: Muscle Nerve Date: 2021-02-02 Impact factor: 3.217
Authors: Samuel Arends; Judith Drenthen; Peter Y K Van den Bergh; Robert D M Hadden; Nortina Shahrizaila; Mazen M Dimachkie; Gerardo Gutiérrez Gutiérrez; Hans Katzberg; Lynette Kiers; Helmar C Lehmann; Yann Péréon; Ricardo C Reisin; Antonino Uncini; Camiel Verhamme; Wagar Waheed; David R Cornblath; Bart C Jacobs Journal: J Peripher Nerv Syst Date: 2022-06-24 Impact factor: 5.188